ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014

Comment on Wang et al.: The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.

Jun Li et al.PubMed ↗Publisher ↗

No numbers read from the abstract.